[Clinical evaluation of imipenem/cilastatin sodium in children].

Abstract

Imipenem/cilastatin sodium (MK-0787/MK-0791) was evaluated for its safety, efficacy and pharmacokinetics in children. Thirty cases of bacterial infections were treated with MK-0787/MK-0791 at a daily dose of 40 to 222 mg/kg for 2.25 to 13 days. Clinical cure rate was 93% and bacteriological efficacy rate was 88%. Treated diseases included severe tonsillitis due to mixed anaerobic infections, pneumonia, sepsis, brain abscess and soft tissue infections. Two cases, one with periosteomyelitis due to methicillin-resistant S. aureus and the other with pulmonary abscess due to Haemophilus influenzae (other than type b), failed to respond to the MK-0787/MK-0791 therapy. The serum half-life of MK-0787 was 0.892 hour in children with normal renal functions. An episode of convulsions in a case of sepsis with bacterial croup and brain edema was considered to be associated with the MK-0787/MK-0791 therapy. From the present study, MK-0787/MK-0791 appears a safe and effective antibiotic when used in children with a variety of bacterial infections.

• Authors: H Meguro, O Arimasu, M Kobayashi, H Shiraishi, R Fujii, K Izumi
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 39 Issue 7 Pg. 1715-32 (Jul 1986) ISSN: 0368-2781 [Print] Japan
• PMID: 3464775 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cyclopropanes
• Drug Combinations
• Thienamycins
• Cilastatin
• Imipenem

Topics

• Bacteria (drug effects)
• Bacterial Infections (drug therapy)
• Child
• Child, Preschool
• Cilastatin
• Cyclopropanes (administration & dosage, adverse effects, metabolism)
• Drug Combinations
• Female
• Humans
• Imipenem
• Infant
• Kinetics
• Male
• Thienamycins (administration & dosage, adverse effects, metabolism)